X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (793) 793
indazoles - therapeutic use (667) 667
index medicus (589) 589
animals (561) 561
male (517) 517
indazoles - pharmacology (449) 449
female (417) 417
oncology (322) 322
middle aged (267) 267
mice (265) 265
antineoplastic agents - therapeutic use (234) 234
pharmacology & pharmacy (234) 234
imidazoles - therapeutic use (221) 221
aged (219) 219
rats (206) 206
adult (198) 198
indazoles - administration & dosage (198) 198
indazoles - adverse effects (179) 179
cancer (157) 157
protein kinase inhibitors - therapeutic use (141) 141
carcinoma, renal cell - drug therapy (139) 139
kidney neoplasms - drug therapy (131) 131
axitinib (130) 130
antineoplastic combined chemotherapy protocols - therapeutic use (118) 118
dose-response relationship, drug (115) 115
cell line, tumor (112) 112
indazoles - chemistry (112) 112
antineoplastic agents - adverse effects (107) 107
treatment outcome (106) 106
enzyme inhibitors - pharmacology (97) 97
nitric oxide (97) 97
chemotherapy (91) 91
analysis (90) 90
chemistry, medicinal (90) 90
antineoplastic agents - pharmacology (87) 87
niacinamide - analogs & derivatives (86) 86
sorafenib (86) 86
nitric oxide synthase - antagonists & inhibitors (85) 85
disease models, animal (84) 84
imidazoles - pharmacology (84) 84
neoplasms - drug therapy (82) 82
care and treatment (81) 81
expression (81) 81
imidazoles - adverse effects (80) 80
sunitinib (79) 79
indazoles - pharmacokinetics (77) 77
neurosciences (75) 75
protein kinase inhibitors - pharmacology (74) 74
pyrazoles - therapeutic use (72) 72
angiogenesis inhibitors - therapeutic use (68) 68
disease-free survival (68) 68
indoles - therapeutic use (68) 68
kidney neoplasms - pathology (68) 68
phenylurea compounds - therapeutic use (67) 67
aged, 80 and over (66) 66
rats, sprague-dawley (66) 66
angiogenesis (65) 65
lung neoplasms - drug therapy (65) 65
rats, wistar (65) 65
lonidamine (64) 64
research (63) 63
inhibition (62) 62
time factors (62) 62
vascular endothelial growth factor (62) 62
bevacizumab (60) 60
endothelial growth-factor (59) 59
enzyme inhibitors - therapeutic use (59) 59
granisetron (59) 59
imidazoles - administration & dosage (59) 59
structure-activity relationship (59) 59
metastasis (58) 58
signal transduction - drug effects (56) 56
article (55) 55
cell proliferation - drug effects (55) 55
drug therapy (55) 55
health aspects (55) 55
antineoplastic agents - administration & dosage (53) 53
tumors (53) 53
activation (52) 52
cell biology (52) 52
pyrroles - therapeutic use (52) 52
apoptosis (51) 51
research article (51) 51
antineoplastic combined chemotherapy protocols - adverse effects (50) 50
carcinoma, renal cell (50) 50
renal cell carcinoma (50) 50
trial (50) 50
biochemistry & molecular biology (49) 49
breast neoplasms - drug therapy (48) 48
protein kinase inhibitors - adverse effects (48) 48
sulfonamides - pharmacology (48) 48
sulfonamides - therapeutic use (48) 48
xenograft model antitumor assays (48) 48
7-nitro indazole (47) 47
drug synergism (47) 47
phase-ii (47) 47
inhibitor (46) 46
nitric-oxide synthase (46) 46
pyridines - therapeutic use (46) 46
therapy (46) 46
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1119) 1119
Japanese (12) 12
French (11) 11
German (11) 11
Italian (4) 4
Hungarian (3) 3
Spanish (3) 3
Chinese (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Treatment Reviews, ISSN 0305-7372, 2016, Volume 50, pp. 109 - 117
Highlights • Survival of patients with mRCC has improved since the advent of targeted therapy. • Identification of prognostic biomarkers may advance... 
Hematology, Oncology and Palliative Medicine | Prognostic markers | Predictive markers | Sequential therapy | Overall survival | Targeted therapy | mRCC | PROGNOSTIC-FACTORS | PROGRESSION-FREE SURVIVAL | 1ST-LINE SUNITINIB | OPEN-LABEL | PHASE-III TRIAL | INTERFERON-ALPHA | ONCOLOGY | DOUBLE-BLIND | 2ND-LINE TREATMENT | CANCER-SPECIFIC SURVIVAL | CLINICAL-PRACTICE | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Kidney Neoplasms - genetics | Bevacizumab - therapeutic use | Prognosis | Humans | Gene Expression Regulation, Neoplastic | Carcinoma, Renal Cell - genetics | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Kidney Neoplasms - metabolism | Vascular Endothelial Growth Factor A - genetics | Sunitinib | Tumor Suppressor Proteins - genetics | Biomarkers, Tumor - metabolism | Axitinib | Everolimus - therapeutic use | Von Hippel-Lindau Tumor Suppressor Protein - genetics | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Nuclear Proteins - genetics | Pyrroles - therapeutic use | Molecular Targeted Therapy - methods | Pyridines - therapeutic use | Histone-Lysine N-Methyltransferase - genetics | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Receptors, CCR4 - genetics | Interferon-alpha - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Transcription Factors - genetics | Ubiquitin Thiolesterase - genetics | Carcinoma, Renal Cell - metabolism | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Carcinoma, Renal Cell - secondary | Nivolumab | Sorafenib | Indoles - therapeutic use | Kidney Neoplasms - pathology | MicroRNAs - genetics | Quinolines - therapeutic use | Mutation | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Precision Medicine - methods | Immunologic Factors - therapeutic use | Antimitotic agents | Care and treatment | Metastasis | Antineoplastic agents | Patient outcomes | Cancer
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9807, pp. 1931 - 1939
Journal Article
British Journal of Cancer, ISSN 0007-0920, 06/2014, Volume 110, Issue 12, pp. 2821 - 2828
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 6, pp. 552 - 562
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2015, Volume 33, Issue 2, pp. 172 - 179
Purpose This open-label phase III trial evaluated efficacy and tolerability of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma... 
ANGIOGENESIS | ONCOLOGY | PATHWAY | SUNITINIB | ABT-869 | RISK | BRIVANIB | INHIBITOR | CANCER | EXPRESSION | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Hand-Foot Syndrome - etiology | Indazoles - administration & dosage | Protein Kinase Inhibitors - adverse effects | Liver Neoplasms - etiology | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Hypertension - chemically induced | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Liver Neoplasms - pathology | Carcinoma, Hepatocellular - etiology | Odds Ratio | Drug Administration Schedule | Risk Factors | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Niacinamide - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Phenylurea Compounds - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Sorafenib | Carcinoma, Hepatocellular - pathology | Aged | Indazoles - adverse effects | Indazoles - therapeutic use | Bone3 | ORIGINAL REPORTS | Bios3
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2016, Volume 375, Issue 22, pp. 2154 - 2164
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 13, pp. 1287 - 1294
Journal Article
Head & Neck, ISSN 1043-3074, 05/2012, Volume 34, Issue 5, pp. 736 - 745
The incidence of thyroid cancer continues to increase and this neoplasia remains the most common endocrine malignancy. No effective systemic treatment... 
epidermal growth factor (EGF) | RET | immunomodulator | vascular disrupting agent | multi‐kinase inhibitor | vascular endothelial growth factor (VEGF) | thyroid cancer | histone acetylation | B‐Raf | heat shock protein (HSP) | multi-kinase inhibitor | B-Raf | SURGERY | HISTONE DEACETYLASE INHIBITOR | ADVANCED SOLID TUMORS | SUBEROYLANILIDE HYDROXAMIC ACID | ABL TYROSINE KINASE | CELL-CYCLE ARREST | VALPROIC ACID | CHRONIC MYELOID-LEUKEMIA | PHASE-II TRIAL | OTORHINOLARYNGOLOGY | GASTROINTESTINAL STROMAL TUMORS | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Bibenzyls - therapeutic use | Humans | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Pyrazines - therapeutic use | Boronic Acids - therapeutic use | Proto-Oncogene Proteins c-kit - antagonists & inhibitors | Thalidomide - analogs & derivatives | Angiogenesis Inhibitors - therapeutic use | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Valproic Acid - therapeutic use | Depsipeptides - therapeutic use | Imidazoles - therapeutic use | Lactams, Macrocyclic - therapeutic use | Pyrroles - therapeutic use | Pyridines - therapeutic use | Bortezomib | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Piperazines - therapeutic use | Imatinib Mesylate | Sulfonamides - therapeutic use | Thyroid Neoplasms - drug therapy | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Quinazolines - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Hydroxamic Acids - therapeutic use | Indoles - therapeutic use | Histone Deacetylase Inhibitors - therapeutic use | Quinolines - therapeutic use | Benzamides | Thalidomide - therapeutic use | Benzoquinones - therapeutic use | Indazoles - therapeutic use | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article